Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.56 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.55 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.50 |
| ▸ | DHODH | Q02127 | 1/20 | 0.50 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.50 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.50 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.50 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.49 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | KMO | O15229 | 2/20 | 0.47 |
| ▸ | RXRA | P19793 | 1/20 | 0.46 |
| ▸ | RXRB | P28702 | 1/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.46 |
| ▸ | DDT | P30046 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.44 |
| ▸ | KDM5A | P29375 | 1/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4366968 | 0.87 | FOLH1 (0.62) | CNR2FOLH1PTPN11DHODHAKR1C2 | |
| SCHEMBL29042413 | 0.86 | FOLH1 (0.69) | FOLH1PTPN11AKR1C2KMORXRA | |
| SCHEMBL29369877 | 0.86 | FOLH1 (0.69) | FOLH1PTPN11AKR1C2KMORXRA | |
| SCHEMBL122524 | 0.85 | CNR2 (0.57) | CNR2DHODHIP6K1IP6K3IP6K2 | |
| SCHEMBL8771736 | 0.84 | HSD17B10 (0.62) | CNR2FOLH1AKR1C2AKR1C1POLB | |
| SCHEMBL594370 | 0.83 | FOLH1 (0.59) | FOLH1PTPN11POLBKMO | |
| SCHEMBL25598474 | 0.83 | CNR2 (0.55) | CNR2DHODHIP6K1IP6K3IP6K2 | |
| SCHEMBL26464789 | 0.82 | GRIK1 (0.55) | CNR2DHODHIP6K1IP6K3IP6K2 | |
| SCHEMBL30361685 | 0.81 | L3MBTL1 (0.59) | CNR2AKR1C2AKR1C1POLBKMO | |
| SCHEMBL268963 | 0.81 | L3MBTL1 (0.59) | CNR2AKR1C2AKR1C1POLBKMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200551-A1 | Flourene Derivative | ASTELLAS PHARMA INC. (JP) | 2008-08-21 | — | — | US | disclosed |
| US-20080171788-A1 | Medicament For Irritable Bowel Syndrome | ASTELLAS PHARMA INC. (JP) | 2008-07-17 | — | — | US | disclosed |
| US-20080161419-A1 | Prophylactic Antimigraine Agents | ASTELLAS PHARMA INC. (JP) | 2008-07-03 | — | — | US | disclosed |
| EP-1852129-A1 | REMEDY FOR IRRITABLE BOWEL SYNDROME | Astellas Pharma Inc. (JP) | 2007-11-07 | — | — | EP | disclosed |
| EP-1728784-A1 | FLUORENE DERIVATIVE | Astellas Pharma Inc. (JP) | 2006-12-06 | — | — | EP | disclosed |
| EP-1716867-A1 | PREVENTIVES FOR MIGRAINE | Astellas Pharma Inc. (JP) | 2006-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161419-A1 | Prophylactic Antimigraine Agents | HTR2B, HTR7, HTR1A | CNR2 32/4885FOLH1 1132/4885PTPN11 3796/4885 |
| US-20080200551-A1 | Flourene Derivative | HTR2B, HTR7, HTR2C | CNR2 52/4885FOLH1 1070/4885PTPN11 2260/4885 |
| US-20080171788-A1 | Medicament For Irritable Bowel Syndrome | HTR7, HTR5A, HTR3B | CNR2 64/4885FOLH1 1280/4885PTPN11 3127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.